Rebus Holdings Inc. (RBSH)
Market Closed
11 Aug, 20:00
OTC PINK OTC PINK Primary $
0. 00
0
0%
$
3.21K Market Cap
- P/E Ratio
- Div Yield
33,943 Volume
- Eps
$ 0
Previous Close Want to track RBSH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
RBSH closed yesterday higher at $0, an increase of 0% from Monday's close, completing a monthly increase of 0% or $0. Over the past 12 months, RBSH stock gained 0%.
RBSH is not paying dividends to its shareholders.
The last earnings report, released on May 10, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Rebus Holdings Inc. has completed 4 stock splits, with the recent split occurring on Oct 12, 2021.
The company's stock is traded on one exchange.
Rebus Holdings Inc. (RBSH) FAQ
What is the stock price today?
The current price is $0.00.
On which exchange is it traded?
Rebus Holdings Inc. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is RBSH.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 3.21K.
Has Rebus Holdings Inc. ever had a stock split?
Rebus Holdings Inc. had 4 splits and the recent split was on Oct 12, 2021.
Rebus Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Raul Silvestre CEO | OTC PINK Exchange | 75619J103 CUSIP |
| US Country | 1 Employees | 30 Jun 2020 Last Dividend | 12 Oct 2021 Last Split | - IPO Date |
Overview
Rebus Holdings, Inc. is a biotechnology company that is dedicated to the innovation and development of precision therapeutics aimed at improving treatment outcomes for cancer patients. With a foundation established in 2003, the company has its headquarters in Westlake Village, California. Rebus Holdings employs cutting-edge research methodologies to discover new therapeutic solutions that address the complex challenges associated with cancer treatment. Their commitment to advancing cancer therapies underlines their primary mission to enhance patient quality of life through innovative science.
Products and Services
- RT-AR001: This is the company’s lead therapeutic asset, which functions as an adenosine receptor antagonist. RT-AR001 is designed to target tumor infiltration specifically, improving the delivery of treatments at the intra-tumoral level. By blocking adenosine receptors, it aims to enhance the immune response against tumors, ultimately leading to better clinical outcomes for patients.
Contact Information
Address: 2629 Townsgate Road
Phone: 818 597 7552
Website: https://www.rebus-corp.com
